RxDoctor Payments DataLook up a doctor →

Sandhya Mani, MD

Pediatric Allergy/Immunology · Baton Rouge, LANPI 1205026770

Payments from drug & device makers

$31,004in general payments, 2019–2025

Across 874 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8K
  • Regeneron$3K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • GSK$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $12K from 44 others

What the payments were for

  • Consulting fees$8,70128%
  • Speaking & faculty fees$2,0257%
  • Travel & lodging$1,4495%
  • Food & beverage$18,61760%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric allergy/immunology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,281
Medicare patients
27
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab73$221,542
Dupixent PenDupilumab22$114,049
NucalaMepolizumab26$90,159
TezspireTezepelumab-Ekko12$53,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,956
Epinephrine30$6,872
SymbicortBudesonide/Formoterol Fumarate23$5,937
Ipratropium Bromide29$1,143
Fluticasone Propionate30$820
Albuterol Sulfate HfaAlbuterol Sulfate17$554
Hydroxyzine Hcl32$481
Famotidine24$273
Montelukast Sodium46$233
Levocetirizine Dihydrochloride23$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta$1,724$111,11448 claims
AstraZenecaTezspire, Symbicort$2,140$59,36235 claims
Hikma Pharmaceuticals USAEpinephrine$15$6,87230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other pediatric allergy/immunology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →